The Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as education… Read more
The Oncology Institute Inc (TOIIW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.029x
Based on the latest financial reports, The Oncology Institute Inc (TOIIW) has a cash flow conversion efficiency ratio of 1.029x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.63 Million) by net assets ($-12.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
The Oncology Institute Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how The Oncology Institute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
The Oncology Institute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of The Oncology Institute Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Palram
TA:PLRM
|
0.047x |
|
PT Carsurin Tbk
JK:CRSN
|
0.107x |
|
Fertilizantes Heringer S.A
SA:FHER3
|
-0.036x |
|
BigBen Interactive
PA:BIG
|
0.208x |
|
Aspen Group Inc
OTCQB:ASPU
|
-0.045x |
|
Renforth Resources Inc
PINK:RFHRF
|
0.068x |
|
Dune Acquisition Corporation II Warrants
NASDAQ:IPODW
|
-0.001x |
|
Herbal Dispatch Inc.
F:HA9
|
0.353x |
Annual Cash Flow Conversion Efficiency for The Oncology Institute Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of The Oncology Institute Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.59 Million | $-26.54 Million | -7.394x | -1061.11% |
| 2023-12-31 | $57.02 Million | $-36.31 Million | -0.637x | -27.02% |
| 2022-12-31 | $123.17 Million | $-61.76 Million | -0.501x | -59.80% |
| 2021-12-31 | $104.16 Million | $-32.68 Million | -0.314x | -1835.57% |
| 2020-12-31 | $28.10 Million | $508.00K | 0.018x | -78.89% |
| 2019-12-31 | $42.22 Million | $3.62 Million | 0.086x | -- |